Insilico Medicine Announces Collaboration with Janssen to Advance AI-Driven Multi-Target Drug Discovery

BEIJING, Nov. 10, 2020 /PRNewswire/ -- InSilico Medicine, a leader in the application of deep generative reinforcement learning technologies for target discovery, small molecule generation, and clinical trial outcome prediction, announced today its collaboration with Johnson & Johnson'sPharmaceuticalsThe subsidiary Janssen Pharmaceutica N.V. signed a multi-target drug discovery agreement.MatchmakingFacilitating this collaboration isJohnson & JohnsonInnovation Limited Liability Company (Johnson & Johnson Innovation LLC)。

Pursuant to the agreement between the parties, InSilico Medicine will design molecules with specific properties targeting the targets proposed by Janssen Pharmaceuticals.Hit Compound Small Molecule, and obtain the advance payment andMilestone PaymentsInSilico Medicine can also play a prominent role during collaborations, demonstrating the drug discovery process and the specific capabilities of its platform.

Since 2015, InSilico Medicine has pioneered the use of generative adversarial networks (GANs) and reinforcement learning (RL) to design novel drug molecules worldwide. The company has published numerous research papers in the field of drug discovery and secured multiple patents, including those covering proof-of-concept studies and experimental validation. In 2020, InSilico Medicine launched its Chemistry42 generative chemistry platform and deployed services within its first cohort of large pharmaceutical companies and drug discovery partner institutions.

"We are honored to collaborate with Janssen Pharmaceuticals, a leader in the most advanced and innovative drug discovery field."One of the Companies“Since 2019, InSilico Medicine has been a resident company at J&J Innovation - JLABS, facilitating closer exchanges with scientists from Janssen Pharmaceuticals and other industry players. We believe this collaboration is a testament to the successful matchmaking by JLABS,” said Dr. Alex Zhavoronkov, Founder and CEO of InSilico Medicine.